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Abstract
Background: The PAX6 protein is a transcriptional regulator with a key role in ocular and
neurological development. Individuals with heterozygous loss-of-function mutations in the PAX6
gene have malformations of the eye and brain. Little is known about the interactions of PAX6 with
other proteins, so we carried out a systematic screen for proteins that interact with PAX6.
Results: We used bioinformatics techniques to characterise a highly conserved peptide at the C-
terminus of the PAX6 protein. Yeast two-hybrid library screens were then carried out to identify
brain-expressed proteins that interact with the C-terminal peptide and with the entire PAX6
proline-serine-threonine-rich domain. Three novel PAX6-interacting proteins were identified: the
post-synaptic density (PSD) protein HOMER3, the dynein subunit DNCL1, and the tripartite motif
protein TRIM11. Three C-terminal PAX6 mutations, previously identified in patients with eye
malformations, all reduced or abolished the interactions.
Conclusion: Our preliminary data suggest that PAX6 interacts with HOMER3, DNCL1 and
TRIM11. We propose that the interaction of PAX6 with HOMER3 and DNCL1 is a mechanism by
which synaptic activation could lead to changes in neuronal transcriptional activity, and that some
of the neural anomalies in patients with PAX6 mutations could be explained by impaired protein-
protein interactions.
Background
The PAX6 protein is a member of the PAX (paired-box)
family of transcriptional regulators and is essential for
normal ocular and neural development [1]. Heterozygous
mutations of the human PAX6  gene cause aniridia
(absence of the iris) and a range of other congenital eye
malformations [2]. Neural defects such as foveal hypopla-
sia and optic nerve hypoplasia are common in PAX6-asso-
ciated eye disease [3-5]. Homozygous mutations in man
and mouse are lethal and result in severe developmental
abnormalities including anophthalmia, severe reduction
of the olfactory structures and gross brain malformations
[2,6]. The roles of PAX6 in brain development have
mainly been studied in homozygous mutant mice or rats
and include arealisation of the cerebral cortex [7], forma-
tion of the prosencephalon-mesencephalon boundary
[8], axon guidance [8], differentiation of neurons from
glia [9] and neuronal migration in the cerebellum [10].
The discovery of multiple and diverse roles for PAX6 in
brain development prompted MRI analyses of aniridia
patients, and a range of distinctive brain anomalies were
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uncovered. The most common and striking of these was
absence or hypoplasia of the anterior commissure [11].
Other defects included absence or hypoplasia of the pin-
eal gland, cortical polymicrogyria, white matter changes
in the corpus callosum and grey matter changes in the cer-
ebellum [11-13]. Functional changes included hyposmia
and abnormal inter-hemispheric auditory transfer
[11,14].
The defining feature of all PAX proteins is the presence of
a 128 amino acid DNA-binding paired domain that has
been highly conserved over evolution [1]. In addition to
the paired domain, PAX6 also contains a DNA-binding
homeodomain and a proline, serine and threonine-rich
(PST) domain at the C-terminus [1,6]. The PST domain,
which encompasses the C-terminal 145 amino acids of
PAX6, has been shown to act as a transcriptional activator
[6]. The PAX6 protein directly regulates a wide range of
target genes [1,2] including Pax2 [15], Ngn2 [16] and glu-
cagon [17].
The Pax6 gene has a spatially and temporally complex
expression pattern in the eye, brain, nasal structures, spi-
nal cord and pancreas [1]. Although PAX6 is clearly
involved in multiple developmental processes, common
themes are now emerging concerning the role of PAX6 in
neural tissues. Gradients of Pax6 expression are important
for determining positional characteristics in the retina
[18] and the neocortex [7]. PAX6 plays a role in develop-
ment of specific axonal connections between the retina
and the brain [18] and within the forebrain [8,19]. It is
also involved in the differentiation of neural cell types
from multipotent precursors in the retina [16] and the cer-
ebral cortex [9] through activation of bHLH genes such as
Ngn2  and  Mash1. These studies provide a clear link
between PAX6 function in the retina and the brain, and
are of particular relevance to the neurological phenotypes
of individuals with PAX6 mutations.
It is becoming apparent that transcription factors do not
act in isolation but are dependent on interactions with
other proteins to carry out their function [20,21]. These
interactions introduce more specificity into the regulatory
function of a given transcription factor. To date only three
PAX6 protein-protein interactions have been described:
with SOX2 on the lens-specific enhancer element of the δ-
crystallin gene [22]; with MDIA, which modulates PAX6
activity in early neuronal development [23], and with
MAF proteins on the glucagon  promoter, which causes
increased expression of this pancreatic hormone gene
[17].
Here we report the preliminary results of the first system-
atic screen for proteins that interact with PAX6. We used
sequence alignment algorithms and secondary structure
prediction programs to define a new domain of 32 amino
acids at the C-terminal end of the PAX6 protein. We then
screened a brain library with this peptide using the yeast
two-hybrid technique and identified three novel interact-
ing proteins, HOMER3, DNCL1 and TRIM11. The interac-
tion between PAX6 and these proteins was disrupted by
naturally occurring C-terminal PAX6 mutations.
Results
A highly conserved C-terminal PAX6 peptide
We and others [31-33] noted that there is significant
sequence conservation at the C-terminal end of the PAX6
protein. BLAST analysis of the amino acid sequence of the
PAX6 PST domain (aa 278–422) revealed a highly con-
served motif within the last 28 amino acids (beginning at
the 'GLISP' motif, Figure 1a). Strong conservation was
seen in distantly related species such as axolotl
(Ambystoma mexicanum) and sea urchin (Paracentrotus
lividus) (Figure 1a).
We subjected the whole PAX6 PST domain to secondary
structure analysis using JPRED, a program that uses a
Characterisation of the PAX6 C-terminal peptide Figure 1
Characterisation of the PAX6 C-terminal peptide. (a) CLUS-
TAL alignment of the terminal 42 amino acids of PAX6 from 
diverse species. (*) indicates invariant residues, (:) indicates 
highly similar substitutions and (.) indicates moderately simi-
lar substitutions. (b) Secondary structure analysis of the 
highly conserved terminal 28 amino acids predicts a single 
beta sheet (arrow) in the SVPVQ peptide. (c) When 4 resi-
dues are added in the N-terminal direction, 2 beta sheets are 
now predicted.BMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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number of different protein structure prediction
algorithms to generate a consensus secondary structure
(Figure 1) [25,26]. The PST domain was largely devoid of
predicted secondary structure except for the C-terminal
region, which contained two predicted beta sheets within
the highly conserved domain, one in the 'GLISP' motif
and one in the 'SPVPQ' motif (identical to the pattern
shown in Figure 1c). Initially we defined the C-terminal
domain as running from the 'GLISP' motif up to the stop
codon, since this region was most highly conserved and
contained strongly predicted secondary structure ele-
ments. However when we performed secondary structure
prediction analysis on this 28 amino acid peptide, the first
beta sheet was lost (Figure 1b). Addition of another 4
amino acids (TTST) immediately before 'GLISP' caused
recovery of the first beta sheet (Figure 1c). Although these
4 residues are not highly conserved (Figure 1a), they
appear to be important for seeding the first beta sheet and
therefore for secondary structure. Thus we define the C-
terminal peptide as being the final 32 amino acids of
PAX6, running from threonine 391 to the stop codon (top
line of Figure 1c).
Yeast two-hybrid screening
We hypothesised that the C-terminal peptide might be
involved in protein-protein interactions, and we tested
this by screening a cDNA library using the yeast two-
hybrid system with a construct (PAX6CTP) in which the
32 amino acid C-terminal peptide was fused to the yeast
GAL4 DNA binding domain. We chose to screen a mouse
brain cDNA library as no human libraries were available.
Given the fact that the amino acid sequence of the PAX6
protein is identical in man and mouse, we reasoned that a
mouse brain library would yield relevant interactors. For
comparison we also carried out the screen using a con-
struct containing the whole PST domain (PAX6PST).
The C-terminal peptide screen gave 15 colonies that were
positive with all three reporters and the PST domain
screen gave 62 colonies. The interacting plasmids were
isolated and the cDNA inserts sequenced. Three cDNAs
were identified 3 or more times, Homer3 (NM_011984),
Dncl1 (Dynein cytoplasmic light chain 1, NM_019682,
also known as Pin or Dlc8) and Trim11 (Tripartite motif
protein family member 11, NM_053168). Homer3  (6
clones) and Dncl1 (2 clones) were identified in the C-ter-
minal peptide screen. Homer3 (7 clones), Dncl1 (2 clones)
and Trim11 (6 clones) were identified in the PST domain
screen. All cDNA inserts were in-frame with the coding
region of the pPC86 GAL4 activation domain. None of
the cDNAs was present in a list of known false positives
[34].
HOMER3 is a member of the HOMER family of neuronal
post-synaptic density (PSD) proteins [35]. DNCL1 is a
subunit of two motor protein complexes, dynein and
myosin-Va, both of which are involved in intracellular
trafficking of proteins and organelles in neurons [36,37].
TRIM11 is a member of the tripartite motif protein family
and contains a RING finger, a B-box zinc finger, a coiled
coil domain and a B30.2 domain [38]. The possible signif-
icance of the interactions between these proteins and
PAX6 is discussed below.
Semi-quantitative PCR
To check that the Homer3, Dncl1 and Trim11 clones were
not identified multiple times solely because they are
highly abundant in the library, we performed a semi-
quantitative PCR assay. We compared the relative abun-
dance of Homer3, Dncl1, Trim11 and Pax6 with Gapdh and
Atp5a1. Gapdh and Atp5a1 both show strong constitutive
expression in a variety of tissues including the brain
[29,30].  Homer3,  Dncl1,  Trim11  and  Pax6  were only
amplified strongly after 35 cycles of PCR (Figure 2) and
were therefore present at relatively low levels compared to
Gapdh  (amplified strongly after 25 cycles) and Atp5a1
(amplified strongly after 30 cycles; Figure 2).
Semi-quantitative PCR analysis of Homer3, Dncl1, Trim11 and  Pax6 in the mouse brain cDNA library Figure 2
Semi-quantitative PCR analysis of Homer3, Dncl1, Trim11 and 
Pax6 in the mouse brain cDNA library. Library cDNA was 
amplified with primers specific for Pax6 (600 bp), Homer3 
(485 bp band), Dncl1 (485 bp) and Trim11 (609 bp) for 20, 25, 
30 or 35 cycles. Atp5a1 (415 bp) and Gapdh (450 bp), which 
are highly expressed in the brain, are included for compari-
son. M indicates the Φ×174 HaeIII DNA size marker; the 
positions of the 603 bp and 310 bp marker bands are 
indicated.BMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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We concluded that Homer3, Dncl1 and Trim11 clones were
not highly abundant in the library. This is consistent with
the idea that they were pulled out because the encoded
proteins interact specifically with the C-terminal peptide
or PST domain of PAX6.
Yeast two-hybrid pairwise interactions
By library screening we identified two proteins (HOMER3
and DNCL1) that interact with the C-terminal peptide
and three proteins (HOMER3, DNCL1 and TRIM11) that
interact with the whole PST domain. This suggests that
HOMER3 and DNCL1 interact specifically with the C-ter-
minal peptide while TRIM11 interacts with a more N-ter-
minal part of the PST domain. We conducted pairwise
tests between specific constructs to confirm the interac-
tions identified in the library screen and to further inves-
tigate the interaction between PAX6 and HOMER3,
DNCL1 and TRIM11. The Dncl1 and Trim11 clones that
were pulled out of the library were full-length, but the
Homer3 cDNAs lacked the N-terminal 70 amino acids. The
missing coding region was inserted into the truncated
Homer3 cDNA to give a full-length expression construct
(see Methods). Pairwise interactions were carried out with
both the full-length and truncated Homer3 clones.
We confirmed that the whole PAX6 PST domain interacts
with HOMER3 (full-length and truncated constructs),
TRIM11 and DNCL1, as all three reporter genes were
strongly activated in pairwise tests (Figure 3; Table 1). In
contrast the interaction between the C-terminal peptide
and HOMER3 or DNCL1 could not be confirmed with
pairwise tests (Table 1). Occasionally, partial suppression
of growth on plates containing 5-fluoro-orotic acid was
observed, indicating low-level activation of the URA3
reporter; however HIS3  and  LacZ  activation were not
observed. The reasons for this are not clear, although it
may be that the pairwise tests were of sub-optimal sensi-
tivity compared to the library screen. However we were
able to confirm that the C-terminal peptide is important
for the interaction with HOMER3 and DNCL1 because
interaction with the PAX6PST-CT construct, which lacks
the final 32 amino acids, was completely abolished (Fig-
ure 3, Table 1). TRIM11 interacted equally well with
PAX6PST and PAX6PST-CT (Figure 3, Table 1). This is
LacZ reporter gene activation in pairwise tests Figure 3
LacZ reporter gene activation in pairwise tests. pPC86 constructs are shown across the top, and pDBLeu constructs are shown 
down the right hand side. PAX6PST, PAX6 PST domain; PAX6PST/Q422R, PAX6 PST domain with the Q422R mutation; 
PAX6PST/X423L, PAX6 PST domain with the X423L mutation, PAX6PST/1615del10, PAX6 PST domain with the 1615 del10 
mutation; PAX6PST-CT, PAX6 PST domain minus the C-terminal peptide. 'Truncated HOMER3' is HOMER3 lacking the N-
terminal 70 amino acids. Five control strains are shown for comparison (left). These range from non-interactor (A) to strong 
interactor (E).BMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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consistent with the library screens in which TRIM11 was
isolated with the PST domain but not with the C-terminal
peptide and supports the idea that the C-terminal peptide
is not important for the interaction between PAX6 and
TRIM11.
Having confirmed that HOMER3, DNCL1 and TRIM11
interact with the PAX6 PST domain, we next investigated
how the interactions were affected by three C-terminal
PAX6 mutations that have been previously described in
patients with ocular anomalies. The first mutation is a
single nucleotide substitution 1627A>G that causes a
glutamine to arginine amino acid substitution in the last
codon of PAX6. This missense mutation (Q422R) has
been reported in two patients, one affected by anterior
segment dysgenesis with uveal ectropion and one with
typical aniridia and foveal hypoplasia [27,33].
The second mutation (1615del10) was found in an ani-
ridia family [28]. This frame-shifting deletion occurs just
before the PAX6  stop codon and is predicted to cause
translational read-through into the 3' untranslated region,
generating a protein in which the last 5 amino acids of the
C-terminal peptide are replaced by a 103 amino acid-
extension. Affected individuals in this family showed unu-
sual neurobehavioural traits including impaired social
cognition and poor verbal inhibition [28]. MRI analysis
revealed grey matter abnormalities in the frontal lobe,
temporal lobe and cerebellum, and white matter deficits
in the corpus callosum [13].
The third mutation 1629insT (X423L) has been reported
in several aniridia patients [11,12,27,33]. Insertion of a
single T nucleotide at position 1629 changes the stop
codon (TAA) to a leucine codon (TTA) and generates a full
length PAX6 protein with a C-terminal extension that
extends for a further 35 amino acids into the 3' untrans-
lated region. MRI analysis of six patients with this muta-
tion revealed variable brain defects including absence or
hypoplasia of the anterior commissure, pineal gland and
olfactory bulbs [12]. Two patients had temporal pol-
ymicrogyria, one in association with epilepsy [12].
The three mutations were introduced into the PAX6PST
construct, and pairwise tests were carried out to investi-
gate the interaction of each mutant protein with
HOMER3, DNCL1 and TRIM11. All three mutations had
a clear effect on the interactions. The most subtle muta-
tion (Q422R) caused a reduction in the interaction with
HOMER3 and DNCL1 (Figure 3, Table 1). The C-terminal
extension mutations X423L and1615del10 mutations
both dramatically reduced or abolished the interaction
with HOMER3 and DNCL1 (Figure 3, Table 1).
None of the three mutations affected the interaction with
TRIM11 which again is consistent with the hypothesis that
TRIM11 interacts with a more N-terminal part of the PST
domain.
Discussion
On the basis of secondary structure predictions and
amino acid sequence conservation, we defined a novel
PAX6 protein domain, which we have called the C-termi-
nal peptide. We performed yeast two-hybrid library
screens with the C-terminal peptide and the whole PST
domain and we identified three novel interacting pro-
teins, HOMER3, DNCL1 and TRIM11. In library screens,
HOMER3 and DNCL1 interacted with the C-terminal
peptide and the PST domain while TRIM11 interacted
only with the PST domain, suggesting that HOMER3 and
DNCL1 specifically interact with the C-terminal peptide
while TRIM11 interacts with a more N-terminal part of the
Table 1: Pairwise interaction tests between normal and mutant PAX6 constructs and HOMER3, DNCL1 and TRIM11. +++: strong 
interaction; ++: moderate interaction; +: weak interaction; (+) borderline interaction with one or two reporters activated at very low 
levels; 0: no interaction. PAX6PST, PAX6 PST domain; PAX6CTP, PAX6 C-terminal peptide; PAX6PST-CT, PAX6 PST domain 
minus the C-terminal peptide; PAX6PST/Q422R, PAX6 PST domain with the Q422R mutation; PAX6PST/X423L, PAX6 PST domain 
with the X423L mutation, PAX6PST/1615del, PAX6 PST domain with the 1615 del10 mutation. HOMER3-FL, HOMER3 full-length 
clone; HOMER3-Tr, truncated HOMER3 clone lacking the N-terminal 70 amino acids.
pDBLeu constructs pPC86 constructs
HOMER3-FL HOMER3-Tr DNCL1 TRIM11
PAX6PST +++ ++ ++ ++
P A X 6 C T P 0000
PAX6PST-CT (+) 0 0 ++
PAX6PST/Q422R ++ + + ++
PAX6PST/X423L + 0 (+) ++
PAX6PST/1615del10 (+) 0 0 ++BMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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PST domain. The interactions between the PST domain
and HOMER3, DNCL1 and TRIM11 were confirmed in
pairwise tests. We were not able to confirm the interaction
between HOMER3 or DNCL1 with the C-terminal peptide
construct in pairwise tests, but we showed that the C-ter-
minal peptide was important for PAX6/HOMER3 or
PAX6/DNCL1 interaction because HOMER3 and DNCL1
did not interact with a PST domain construct lacking the
C-terminal peptide.
HOMER3 is found in the PSD of neurons and directly
binds to type I metabotropic glutamate receptors, which
act via phospholipase C to stimulate IP3-mediated release
of Ca2+ from intracellular vesicles [35,39]. HOMER3 is a
member of the HOMER family of proteins that are consti-
tutively expressed in the brain and play a role in post-syn-
aptic signalling and receptor trafficking by forming
multivalent links with various receptors and PSD scaffold-
ing proteins [35,39-41]. HOMER proteins have also been
implicated in axon guidance during brain development
[42].
DNCL1 is a subunit of two intracellular transport protein
complexes, dynein and myosin Va [36]. Dynein and
myosin Va are involved in the microtubule-based and
actin-based movement respectively of proteins, organelles
and vesicles in neurons [36,37]. Myosin Va is enriched in
the PSD [43], and DNCL1 binds to a variety of PSD pro-
teins including guanylate kinase domain-associated pro-
tein [44] and neuronal nitric oxide synthase [45].
TRIM11 is a member of the mouse tripartite motif protein
family (also known as the RBCC family), and contains the
three characteristic structural motifs of this protein family,
a RING finger, a B-box zinc finger, and a coiled coil
domain, as well as a B30.2 domain that is found in many
but not all TRIM proteins [38]. TRIM11 interacts with
Humanin, a protein that suppresses the neurotoxicity
associated with Alzheimer's disease [46]. TRIM11 lowers
Humanin levels by a mechanism that appears to involve
ubiqutin-mediated proteasomal degradation [46].
At present our data must be considered preliminary
because the interactions have not been confirmed by any
other approach. However it is interesting to speculate that
the interaction of PAX6 with HOMER3 and DNCL1 may
be the basis of a mechanism by which synaptic signalling
causes changes in gene expression. We propose that PAX6
is sequestered in the PSD by binding to HOMER3. Since
receptor activation causes dissociation of HOMER pro-
teins [35], PAX6 may be released as a result of synaptic
activity, allowing it to interact with DNCL1. The PAX6/
DNCL1 complex could then participate in myosin Va-
mediated transport along the PSD-associated actin
cytoskeleton followed by dynein-mediated transport
along the microtubule network, eventually reaching the
nucleus [36]. Since TRIM11 is implicated in protein deg-
radation [46], it may play a role in PAX6 protein turnover.
Precedents for association of transcription factors with the
post-synaptic density include STAT3 and CREB, which act
as messengers between the synapse and the nucleus
[47,48]. Although the full-length PAX6 protein is predom-
inantly nuclear, there is good evidence in mouse, quail
and nematode for an isoform that lacks the paired
domain, is both nuclear and cytoplasmic, and binds DNA
through the homeodomain alone [49-51]. In mice the
paired-less isoform is relatively abundant in brain [49];
however its subcellular localisation in neurones, and the
possibility of an association with the PSD, remains to be
investigated.
Regarding the subcellular localisation of the putative
interacting proteins, HOMER3 is predominantly found at
the interface between the PSD and the cytoplasm [39],
DNCL1 is chiefly cytoplasmic, although nuclear localisa-
tion has been reported [51], and TRIM11 is both nuclear
and cytoplasmic [38]. Therefore cytoplasmic PAX6 could
potentially interact with all three proteins, while nuclear
PAX6 could interact with TRIM11 and DNCL1. At the tis-
sue level, HOMER3 expression has been detected in thy-
mus and lung but it has mainly been studied in brain
where it is found in the forebrain, hippocampus and cer-
ebellum [39]. DNCL1 and TRIM11 both have wide
expression domains that include the brain [44,38]. Thus
the expression of all three interactors overlaps with PAX6
at the tissue level [2,7,8,10]. We detected co-expression of
PAX6,  HOMER3,  DNCL1  and  TRIM11  by RT-PCR in
human adult brain RNA (IH, L Harrison and A Brown,
data not shown).
We demonstrated that the interaction between the PST
domain and HOMER3 or DNCL1 was impaired by three
naturally occurring mutations that are located in the PAX6
C-terminal peptide. The Q422R mutation, which involves
a glutamine to arginine substitution at the last amino acid
position of PAX6, caused a reduction in the interaction
with HOMER3 and DNCL1. The X423L and 1615del10
mutations severely reduced or completely abolished the
interaction with HOMER3 and DNCL1. The predicted
effect of the X423L and 1615del10 mutations is to cause
translation into the 3' untranslated region, thus generat-
ing proteins with abnormal extensions that might be
expected to disrupt the conformation of the C-terminal
end of the protein. The 1615del10 mutation also removes
the last 5 amino acids of the C-terminal peptide [28].
None of the mutations affected the interaction with
TRIM11, suggesting that they do not alter the
conformation of the more N-terminal part of the PSTBMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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domain. All our data are consistent with the hypothesis
that TRIM11 does not interact with the C-terminal pep-
tide, but interacts with the PST domain between the
homeodomain and the C-terminal peptide.
Most aniridia patients are heterozygous for mutations that
introduce a premature termination codon into the PAX6
open reading frame [2,52]. These alleles would be
expected to encode truncated proteins or no protein at all
if the mutant RNA is degraded by nonsense-mediated
decay [52]. We propose that the brain anomalies that have
been observed in aniridia patients may be partly
explained by impaired interaction between PAX6 and
HOMER3, DNCL1 and TRIM11. The neurobehavioural
phenotype associated with 1615del10 and the polymicro-
gyria associated with X423L may result from a specific
effect of these unusual C-terminal extension mutations.
There is evidence that signalling and transport mecha-
nisms that were initially characterized in the brain may
also be conserved in the retina, suggesting that impaired
PAX6 protein-protein interactions may also have
implications for the retinal defects observed in individuals
with PAX6 mutations [53,54].
Conclusion
We have presented preliminary evidence that the neu-
rodevelopmental transcriptional regulator PAX6 interacts
with HOMER3, DNCL1 and TRIM11. We suggest that the
interaction of PAX6 with HOMER3 and DNCL1 is a mech-
anism by which synaptic signalling could lead to regu-
lated changes in gene expression in neurons. We also
propose that some of the neural anomalies in patients
with PAX6 mutations may be explained by impaired pro-
tein-protein interactions.
Methods
Bioinformatics techniques
Sequence database searches were carried out using the
BLAST program available through the Bioinformatics
Applications at the Rosalind Franklin Centre for Genom-
ics Research [24]. Protein sequences that were highly
homologous to the C-terminus of human PAX6 were
aligned using CLUSTAL [24]. Secondary structure predic-
tion was performed using the JPRED consensus method
[25,26].
Yeast two-hybrid constructs
All cDNA and amino acid numbering is based on the
human PAX6 cDNA and protein reference sequences
available from the Human PAX6 Allelic Variant Database
web site [27]. Standard PCR and subcloning techniques
were used to make three PAX6 cDNA constructs in the
pDBLeu expression vector (ProQuest Two-Hybrid System,
Invitrogen), which generates a protein fused to the yeast
GAL4 DNA binding domain. PAX6PST contains the
whole PST domain (amino acids 278–422 of the full-
length PAX6 protein). Primers were ST001 (forward) 5'-
AAA AGT TCG ACT GCC AGC AAC ACA CCT AGT C-3'
and ST005 (R) 5'-TTT TGC GGC TTT TTA CTG TAA TCT
TGG CCA GTA TTG-3'. PAX6CTP contains the newly
defined C-terminal peptide alone (391–422). Primers
were ST004 (F) 5'-AAA AGT CGA CTA CCA CTT CAA CAG
GAC TCA TT-3' and ST005 (R). PAX6PST-CT contains the
PST domain minus the C-terminal peptide (278–390).
This was made by cutting PAX6PST with NdeI and NotI to
drop out the C-terminal peptide, and inserting a synthetic
linker between the two restriction sites. All fragments gen-
erated by PCR or with linkers were sequenced to check
that no errors had been introduced.
A PAX6 PST domain construct containing the mutation
1627A>G (Q422R) was generated in the same way as the
PAX6PST construct, but using the reverse PCR primer
ST006 5'-TTT TGC GGC CGC TTT TTA CCG TAA TCT TGG
CCA GTA TTG AG-3', which contains the mutant nucle-
otide substitution (underlined).
cDNA sequences containing the mutations 1615del10
[28] and 1629insT (X423L) [12] were generated by PCR
from reverse transcribed RNA (a gift from Dr K William-
son and Prof V van Heyningen). Primers were ST015 (F)
5'-CCC ACA TAT GCA GAC ACA C-3' and ST031 (R) 5'-
TTG CGG CCG CAT CCA TCC AGT CTA CAT TGT TC-3'.
The PAX6PST construct was cut with NdeI and NotI to
release the normal C-terminal peptide, and the mutant
sequence was inserted.
Yeast two-hybrid library screens
A mouse brain cDNA library (ProQuest, Invitrogen) was
screened with the PAX6PST and PAX6CTP pDBLeu con-
structs. The library was constructed in the pPC86 vector,
which produces proteins fused to the yeast GAL4 activa-
tion domain. The system uses three GAL4-activated
reporter genes, HIS3, URA3 and lacZ, to identify positive
interactions. Reporters are activated when the bait protein
fused to the GAL4 DNA binding domain (pDBLeu) inter-
acts with the prey protein fused to the GAL4 activation
domain (pPC86), thus reconstituting GAL4 function.
HIS3 activation allows growth on plates lacking histidine.
Weak URA3 activation suppresses growth on plates con-
taining 5-fluro-orotic acid while strong URA3 activation
permits growth on plates lacking uracil. LacZ activation
causes X-gal to turn blue in a beta-galactosidase assay. All
assays were carried out in parallel with the five ProQuest
control yeast strains A-E, which range from non-interactor
(A) to strong interactor (E).
All procedures were carried out according to the supplier's
protocols. Briefly, chemically competent MaV203 yeast
cells were co-transformed with the cDNA library and theBMC Genetics 2005, 6:43 http://www.biomedcentral.com/1471-2156/6/43
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bait plasmid pDBLeu PAX6CTP or pDBLeu PAX6PST.
Transformants (5 × 107) were plated on medium lacking
histidine to check for HIS3 activation. HIS3 positives were
then assayed for all 3 reporters. The pPC86 prey plasmid
was isolated from all HIS3/URA3/LacZ positives and the
cDNA insert sequenced. BLAST searches were performed
to identify the cDNA insert [24].
Pairwise interactions
Specific interactions were tested by transforming compe-
tent MaV203 yeast cells with one bait construct (in pDB-
Leu) and one prey construct (in pPC86) and testing the
resulting colonies for activation of the HIS3, URA3 and
LacZ reporters as before.
To create a full-length Homer3 clone for pairwise tests, a
cDNA clone (IMAGE clone 3602414, accession number
BE569374) containing the missing N-terminal 70 amino
acids was identified by a BLAST search of the EST nucle-
otide sequence database and obtained from the Rosalind
Franklin Centre for Genomics Research. The missing frag-
ment was amplified from the IMAGE clone by PCR and
inserted into the pPC86-Homer3 plasmid to create a full-
length expression construct.
Semi-quantitative PCR
To check the relative representation of clones in the cDNA
library, semi-quantitative PCR was performed on Pax6,
Homer3, Dncl1, Trim11 and the constitutively expressed
genes Gapdh and Atp5a1 [29,30]. Primers were designed to
cross at least one intron, so that only correctly spliced
clones were amplified. Primer sequences were: Pax6-F
CAG CCA AAA TAG ATC TAC CTG; Pax6-R CGA TCA CAT
GCT CTC TCC TT; Homer3-F CCC AGG TGG CTG TAG
AGC; Homer3-R CTC TAC ACA GTG CAA AGC TCA G;
Trim11-F GTG CAG GAT GTG AAG CTG; Trim11-R GCC
TGC AGA TAG TCA TAG GG; Dncl1-F CAA AAA TGC AGA
CAT GTC G; Dncl1-R CTA AGG GAG AAA AAA ATG GGG;
Gapdh-F: CAT CAC CAT CTT CCA GGA GC; Gapdh-R:
ATG ACC TTG CCC ACA GCC TT; Atp5a1-F: CAC ACG
TGA GAT GTC CTC CA; Atp5a1-R: CAC AGA GAT TCG
GGG ATA A. 10 ng library cDNA were amplified in a
reaction containing 1xAmpliTaq polymerase buffer (Per-
kin Elmer), 1.5 mM MgCl2, 200µM each primer and 2.5
units of AmpliTaq polymerase (Perkin Elmer). PCR condi-
tions were (95°C for 30 sec) × 1, (94°C for 30 sec, 55°C
for 30 sec, 72°C for 30 sec) × 32 and (72°C for 2 min) ×
1. Products were resolved on a 2.5% agarose gel with
ΦX174/HaeIII size markers (Promega).
Abbreviations
PST domain, proline-, serine- and threonine-rich domain;
PSD, post-synaptic density; PCR, polymerase chain
reaction.
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